中文名称: | 雷夫康唑 | ||||
---|---|---|---|---|---|
英文名称: | Ravuconazole | ||||
别名: | 雷夫康唑 BMS-207147; ER-30346 | ||||
CAS No: | 182760-06-1 | 分子式: | C22H17F2N5Os | 分子量: | 437.47 |
CAS No: | 182760-06-1 | ||||
分子式: | C22H17F2N5Os | ||||
分子量: | 437.47 |
基本信息
产品编号:R10203 |
|||||
产品名称:Ravuconazole |
|||||
CAS: |
182760-06-1 |
储存条件 |
粉末 |
-20℃ |
四年 |
分子式: |
溶于液体 |
-80℃ |
六个月 |
||
分子量 |
437.47 |
-20℃ |
一个月 |
||
化学名: |
|||||
Solubility (25°C) |
体外 |
DMSO |
≥50mg/mL (114.29mM) |
||
Ethanol |
|
||||
Water |
|
||||
体内 |
现配现用 |
|
|||
<1mg/ml表示微溶或不溶。 |
|||||
普西唐提供的所有化合物浓度为内部测试所得,实际溶液度可能与公布值有所偏差,属于正常的批间细微差异现象。 |
|||||
请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;⼀旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 |
制备储备液
浓度
溶液体积 质量 |
1mg |
5mg |
10mg |
1mM |
2.2859mL |
11.4294mL |
22.8587mL |
5mM |
0.4572mL |
2.2859mL |
4.5717mL |
10mM |
0.2286mL |
1.1429mL |
2.2859mL |
生物活性
产品描述 |
一种口服的三唑抗真菌药物,能够有效广谱的抑制真菌。 |
靶点/IC50 |
Fungal |
体外研究 |
Ravuconazole shows a broad spectrum of activity against a wide range of fungi covering Candida spp., Trichosporon beigelii,C. neoformans and A. fumigatus. The MIC90 ranges from 0.025 to 0.39mg/mL.Ravuconazoleshows relatively higher levels of activity against three strains of Candida krusei, with MICs ranging from 0.05 to 0.39mg/mL.Ravuconazoleshows good activity against T. mentagrophytes, T. rubrum, M. gypseum and M. caniswith MICs ranging from 0.05 to 0.39 mg/mL.Ravuconazoleis about two- to four fold more potent than itraconazole and about 40-fold more active than fluconazole against yeasts. Ravuconazoleand itraconazoleare inhibitory to most aspergilli, and against half of the isolates, the activity iscidal. Ravuconazoleand itraconazoleare active, though not cidal, against most hyaline Hyphomycetes, dermatophytes, and the dematiaceous fungi and inactive against Sporothrix schenckii and zygomycetes |
体内研究 |
The maximum concentration of ravuconazole in plasma and the area under the concentration-time curve for ravuconazoleshow good linearity over a range of doses from 2 to 40mg/kg of body weight. Ravuconazole at a dose of 2.5mg/kg delays mortality significantly compared with the control treatment.Ravuconazole also shows a substantial therapeutic effect against systemic cryptococcosis. Ravuconazole reduces the numbers of CFU in the lungs significantly compared with the numbers of CFU in the lungs of the controls. In an experimental model of oral candidiasis in rats, ravuconazole reduces the numbers of CFU in oral swabs significantly compared with the numbers of CFU in oral swabs from the controls and is more effective than itraconazole and as effective as fluconazole. |
推荐实验方法(仅供参考)
动物实验: |
|
Animal Administration |
Mouse Ravuconazole is prepared in 10% DMSO in 0.5% CMC.C. neoformans No. 3 is grown on an SDA plate at 30℃for 48h, and challenge organisms are prepared in sterile saline. Mice (age, 5weeks; n 5 10) are infected via the tail vein. Ravuconazole are orally administered, in a volume of 0.2mL per dose, twice daily for 5 consecutive days starting 1h after infection. Controls receive 10% DMSO in 0.5% CMC. Ravuconazole are administered at doses of 8 and 32mg/kg. Mortality is recorded daily for 21days of infection. Drug efficacy is assessed by determining the delay in mortality. Rats The rats are orally infected three times at 48-h intervals with 0.1mL of a saline suspension containing cells of C. albicans E81022. Ravuconazoleis orally administered, in a volume of 0.5mL per dose, once daily for 3 consecutive days starting 2days after the last infection. Control groups receive 10% DMSO in 0.5% CMC. Drugs are administered at doses of 1 and 4mg/kg. Drug efficacy is assessed 5 days after the last infection by measuring the number of C. albicansorganisms in oral swabs. |
本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:
质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)
摩尔浓度计算公式
用本工具协助配置特定浓度的溶液,使用的计算公式为:
开始浓度 x 开始体积 = 最终浓度 x 最终体积
稀释公式
稀释公式一般简略地表示为:C1V1 = C2V2 ( 输入 输出 )